Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-25

FDA Approved: NEBIVOLOL — Supplemental Application (ANI Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves ANI Pharmaceuticals' supplemental application for Nebivolol, enabling a generic nebivolol product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nebivolol (Nebivolol)

Snippet

SUPPL AP for NEBIVOLOL (NEBIVOLOL)